A prominence of both of these cytokines in NMOSD is consistent with clinical evidence, where IFN-β therapy exacerbates disease severity and increases relapse rates [148–152], in contrast to patients with MS where IFN-β ameliorates disease [153]. This evidence concerns the gene IFNB1 and myeloid sarcoma.